

CURRICULUM VITAE

Name: Andrés Cervantes Ruipérez, MD, PhD.

Date of birth: January 31st, 1957

Place of birth: Cartagena (Murcia), Spain

Country of Citizenship: Spain

Office Address: Medical Oncology Department
Hospital Clínico de Valencia
Av. Blasco Ibáñez, 17
46010 Valencia, Spain

Education and Training

- 1974-1980 MD, School of Medicine – Universidad de Murcia, Murcia, Spain
- 1982-1986 Medical Oncology resident, Hospital Clínico Universitario de Valencia, Valencia, Spain
- 1986-1987 Fellow, Free University, Amsterdam, Holland. Laboratory of Dr. Bob Pinedo
- 1987 PhD, Universitat de València, Valencia, Spain
- 2018 Healthcare Management Program. IESE Business School. Madrid, Spain

Professional Experience

- 1987-1988 Physician, Department of Hematology and Medical Oncology, Hospital General de Alicante, Alicante, Spain
- 1988-2006 Physician, Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain
- 1992-2017 Professor, Medicine Department, Universitat de València, Valencia, Spain

- 2006-2015 Head of Section, Department of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain
- 2015-present Head of Department, Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
- 2017-present Full Professor, Medicine Department, Universitat de València, Valencia, Spain
- 2017-present General Director, Biomedical Research Institute - INCLIVA

Current Institutional Responsibilities

- 2015-present Head of the Department of Medical Oncology in the Hospital Clínico Universitario de Valencia
- 2017-present General Director and Scientific Director of the Biomedical Research Institute – INCLIVA

Editorial Boards

- Cancer Treatment Reviews, Editor-in-Chief, since 2013
- Annals of Oncology, Editor-in-Chief since 2014
- Lancet, Ad-hoc reviewer
- Lancet Oncology, Ad-hoc reviewer
- Nature Communications, Ad-hoc reviewer
- European Journal of Cancer, Ad-hoc reviewer
- Annals of Oncology, Ad-hoc reviewer
- Clinical Cancer Research, Ad-hoc reviewer
- Journal of Clinical Oncology, Ad-hoc reviewer
- Nature Reviews in Clinical Oncology, Ad-hoc reviewer

Publications

1.- Lluch A, Artero A, Cervantes A, Vicent JM, Codina G, Barrajon G, Rabena MT, Alberola V, Garcia Conde J.

Estrogen and progesterone receptors in cancer of the breast
Medicina Clínica (Barc). 1987 Oct 10;89(11):456-9

2.- Cervantes A, Pinedo HM, Lankelma J, Schuurhuis GJ.

The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells
Cancer Lett. 1988 Aug 15;41(2):169-77

3.- Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen TH, de Lange JH, Baak JP, Pinedo HM, Lankelma J.

Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.
J Natl Cancer Inst. 1989 Dec 20;81(24):1887-92

4.- Cervantes A, Busquier I, Llobart A, Garcia-Conde J.

The autopsy in modern oncology: a quality assessment of clinical care
Ann Oncol. 1991 Feb;2(2):130

5.- Díaz-Rubio E, Jimeno J, Aranda E, Massuti B, Camps C, Cervantes A, Dorta J, Cruz Hernández JJ, Dominguez S, Anton A, et al.

Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.).
Ann Oncol. 1992 Dec;3(10):861-3.

6.- Schuurhuis GJ, van Heijningen TH, Cervantes A, Pinedo HM, de Lange JH, Keizer HG, Broxterman HJ, Baak JP, Lankelma J.

Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Br J Cancer. 1993 Nov;68(5):898-908.

7.- Cervantes A, Villar-Grimalt A, Abad A, Anton-Torres A, Belon J, Dorta J, Tres A, Camps C, Fonseca E, Massuti B, et al.

5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Ann Oncol. 1993 Nov;4(9):753-7.

8.- Aranda E, Cervantes A, Dorta J, Blanco E, Fernandez-Martos C, Cruz-Hernandez JJ, Carrato A, Gonzalez-Mancha R, Garcia-Conde J, Diaz-Rubio E.

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

Cancer. 1995 Aug 15;76(4):559-63

9.- Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF, et al.

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

Eur J Cancer. 1996 May;32A(5):807-13.

10.- Aranda E, Cervantes A, Carrato A, Anton-Torres A, Massuti T, Fernandez-Martos C, Diaz-Rubio E.

The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).

J Infus Chemother. 1996 Summer;6(3):118-22.

11.- Aranda E, Cervantes A, Carrato A, Fernandez-Martos C, Anton-Torres A, Massuti T, Barneto I, Garcia-Conde J, Baron JM, Diaz-Rubio E.

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

12.- Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D

Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-40-S15-43

13.- Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Antón A, Vicent JM, Dorta J, Garcia de Paredes ML, Ariza A.

Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial.

Am J Clin Oncol. 1998 Apr;21(2):151-4.

14.- Aranda E, Diaz-Rubio E, Cervantes A, Anton-Torres A, Carrato A, Massuti T, Tabernero JM, Sastre J, Tres A, Aparicio J, Lopez-Vega JM, Barneto I, Garcia-Conde J.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.

Ann Oncol. 1998 Jul;9(7):727-31

15.- Diaz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallen M, Marcuello E, Rifa J, Massuti T, Cervantes A, Anton A, Fernandez Martos C.
UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients
Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):35-40

16.- Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Boes GH, Pecorelli S.
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
Eur J Obstet Gynecol Reprod Biol. 1999 Oct;86(2):179-83.

17.- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol. 2000 Aug;18(16):2938-47.

18.- Wagenaar HC, Colombo N, Vergote I, Hochtin-Boes G, Zanetta G, Pecorelli S, Lacave AJ, van Hoesel Q, Cervantes A, Bolis G, Namer M, Lhomme C, Guastalla JP, Nooij MA, Poveda A, Scotto di Palumbo V, Vermorken JB.
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Gynecol Oncol. 2001 Jun;81(3):348-54.

19.- Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B.
Raltitrexed: current clinical status and future directions.
Ann Oncol. 2002 Apr;13(4):513-22. Review.

20.- De Gramont a, Schmoll HJ, Cervantes A, Tournigand C.
The evolving role of oxaliplatin in the management of colorectal cancer
Colorectal Dis. 2003 Nov;5 Suppl 3:10-9. Review.

21.- Alberts SR, Cervantes A, van de Velde CJ.
Gastric cancer: epidemiology, pathology and treatment.
Ann Oncol. 2003;14 Suppl 2:ii31-6. Review

22.- Martínez Ferrandis JI, Vega A, Chirivella I, Marín García P, Insa A, Lluch Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations
Hum Mutat. 2003 Nov;22(5):417-8.

23.- van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. *Ann Oncol.* 2003 Mar;14(3):441-8

24.- Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodriguez-Lopez R, Velasco E, Chaves J, Diaz-Rubio E, Jesus Cruz J, Torres M, Esteban E, Cervantes A, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects *Hum Mutat.* 2003 Oct;22(4):301-12.

25.- Anton A, Aranda E, Carrato A, Marcuello E, Massutti B, Cervantes A, Abad A, Sastre J, Fernández Martos C, Gallen M, Díaz Rubio E, Huarte L, Balcells M. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. *Methods Find Exp Clin Pharmacol.* 2003 Oct;25(8):639-43

26.- Aranda E, Carrato A, Cervantes A, Sastre J, Gomez MA, Abad A, Masutti B, Ribera F, Marcuello E, Pronk L, Balcells M, Diaz-Rubio E Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. *Ann Oncol.* 2004 Apr;15(4):559-67.

27.- Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). *J Natl Cancer Inst.* 2004 Mar 17;96(6):487-8

28.- Lledo SM, Garcia-Granero E, Dasi F, Ripoli R, Garcia SA, Cervantes A, Alino SF Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. *Colorectal Dis.* 2004 Jul;6(4):236-42.

29.- Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. *Gynecol Oncol.* 2004 Oct;95(1):114-9.

30.- Cervantes A, Chirivella I.

Oncological emergencies.

Ann Oncol. 2004;15 Suppl 4:iv299-306. Review.

31.- Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Anton A, Martinez-Villacampa M, Marcuello E, Massuti B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

Clin Colorectal Cancer. 2005 Mar;4(6):384-9.

32.- Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Anton A, Martinez-Villacampa M, Marcuello E, Massuti B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

Clin Colorectal Cancer. 2005 Mar;4(6):384-9

33.- Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, Cervantes A. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study

Ann Oncol. 2005 May;16(5):749-55

34.- Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, Manzano H, Chirivella I, Gallego R, Marfa X.

Phase I trial of oxaliplatin in combination with cisplatin, protracted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):91-6.

35.- Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulas V, Hussein F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, et al

Capecitabine as adjuvant treatment for stage III colon cancer

N Engl J Med. 2005 Jun 30;352(26):2696-704.

36.- Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U.

Integration of new or experimental treatment options and new approaches to clinical trials.

Ann Oncol. 2005;16 Suppl 8:viii30-viii35

37.- Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration

Ann Oncol. 2005;16 Suppl 8:viii36-viii38.

38.- du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, et al

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIg OCCC 2004

Ann Oncol. 2005;16 Suppl 8:viii7-viii12

39.- Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

J Clin Oncol. 2005 Dec 1;23(34):8636-45

40.- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study.

J Clin Oncol. 2006 Jan 20;24(3):394-400

41.- Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J and Díaz-Rubio E.

Guides for adjuvant treatment of colon cancer.

Clin Transl Oncol. 2006 Feb;8(2):98-102.

42.- Navarro M, Dotor E, Rivera F, Sánchez-Rovira P, Vega-Villegas ME, Cervantes A, García JL, Gallén M and Aranda E.

A phase II study of preoperative radiotherapy and concomitant weekly Irinotecan in combination with protracted venous infusion 5-Fluorouracil, for resectable locally advanced rectal cancer.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5

43.- Cervantes A, Chirivella I, Rodríguez-Braun E, Campos S, Navarro S & García-Granero E.

A multimodality approach to localized rectal cancer

Ann Oncol. 2006 Sep;17 Suppl 10:x129-34

44.- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

J Clin Oncol. 2006 Jan 20;24(3):394-400

45.- Cervantes A, Chirivella I, Rodríguez-Braun E, Campos S, Navarro S & García-Granero E.

A multimodality approach to localized rectal cancer.

Revista: Annals of Oncology

Ann Oncol. 2006 Sep;17 Suppl 10:x129-34

46.- Macarulla T, Valverde C, Ramos FJ, Casado E, Martinelli E, Cervantes A, Tabernero J.

Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies.

Targ Oncol. 2006, 1: 23 -33.

47.- Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J and Díaz-Rubio E.

Guides for adjuvant treatment of colon cancer.

Clin Transl Oncol. 2006 Feb;8(2):98-102

48.- Navarro M, Dotor E, Rivera F, Sánchez-Rovira P, Vega-Villegas ME, Cervantes A, García JL, Gallén M and Aranda E.

A phase II study of preoperative radiotherapy and concomitant weekly Irinotecan in combination with protracted venous infusion 5-Fluorouracil, for resectable locally advanced rectal cancer.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5.

49.- Macdonald J, Cervantes A.

New horizons for gastric cancer: commentary

Ejc Supplements 2006, 4-10: 1-3.

50.- Cervantes A, Chirivella I, Roselló S.

Tratamiento del cáncer epitelial de ovario avanzado.

Formación Médica Continuada, 2006, 1-2:32-43.

51.- Chirivella Gonzalez I, Teruel Casasús A, Magro Molina A, Insa Molla A, Rodriguez Braun E, Cervantes Ruiperez A.

Phlegmasia cerulea dolens in patients with testicular carcinoma

Actas Urológicas Españolas.2006, 30-10: 1043-1045.

- 52.- Cervantes A, Rodriguez Braun E, Perez Fidalgo A, Chirivella Gonzalez I.
Molecular biology of gastric cancer.
Clin Transl Oncol. 2007 Apr;9(4):208-15
- 53.- Martínez-Ferrandis JL, Soriano MA, Martinez-Romero A, Herrera G, Cervantes A, O'Connor JE, Knecht E, Armengod ME
Cytometry A. 2007 Aug;71(8):599-604
Revista: Cytometry Part a
- 54.- Pavlidis N, Vermorken JB, Stahel R, Bernier J, Cervantes A, Audisio R, Pentheroudakis G, Costa A
Oncology for medical students: A European School of Oncology contribution to undergraduate cancer education
Cancer Treat Rev. 2007 Aug;33(5):419-26
- 55.- Martínez-Ferrandis JI, Rodríguez-López R, Milne R, González E, Cebolla E, Chirivella I, Zamora P, Arias J, Palacios S, Cervantes A, Díez O, Benítez J, Armengod ME
Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women
Cancer Biomark. 2007;3(2):89-93
- 56.- Cervantes A, Rodríguez-Braun E, Navarro S, Hernández A, Campos S & García-Granero E.
Integrative decisions in rectal cancer
Ann Oncol. 2007 Jul;18 Suppl 9:ix127-31
- 57.- Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella I.
La quimioterapia en el tratamiento del cáncer de esófago.
Revisiones en Cancer 2007; 21-2:102-112.
- 58.- Poveda A, Casado A, Cervantes A, Gallardo D, García García E, González Martín A, López García G, Mendiola C, Ojeda B
Treatment guidelines in ovarian cancer.
Clinical & Translational Oncology 2007, 9-5: 308-316.
- 59.- de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, Tournigand C.
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
J Clin Oncol. 2007 Aug 1;25(22):3224-9
- 60.- Ivorra P, Sabater L, Calvete J, Camps B, Cervantes A, Bosch A, Plazzotta C, Cassinello N, Arlandis P, Lledó S.
Efecto de la quimioterapia neoadyuvante en los resultados de la cirugía de resección de las metástasis hepáticas de origen colorrectal
Cirugia Espanola. 2007; 82-3: 166-171.

- 61.- Pérez-Fidalgo JA, Chirivella I, Günthner S, Cervera JI, March JA, Cervantes A.
La encefalopatía hiperamonémica, una posible complicación por derivación urinaria tras cistectomía radical. Revisión de la literatura a propósito de un caso.
Revista: Actas Urológicas Españolas
- 62.- Figer A, Pérez-Staub N, Carola E, Tournigand C, Lledó G, Flesch M, Barceló R, Cervantes A, André T, Colin P, Louvet C, De Gramont A.
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Cancer. 2007 Dec 15;110(12):2666-71
- 63.- Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Sastre J, Tortora G, Ciardiello F, Kisker O, De Gramont A.
Phase II trial of Cetuximab in combination with Fluorouracil, Leucovorin, and Oxaliplatin in the first-line treatment of metastatic colorectal cancer.
J Clin Oncol. 2007 Nov 20;25(33):5225-32
- 64.- Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A.
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial
Br J Cancer. 2008 Aug 5;99(3):455-8. doi: 10.1038/sj.bjc.6604530
- 65.- Cervantes A.
Panitumumab: una nueva opción en el tratamiento del cáncer de colon.
Revisiones en Cancer 2007; 22,Supl. 1 : 67-68.
- 66.- Tabernero J, Pfeiffer P, Cervantes A.
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
Oncologist. 2008 Feb;13(2):113-9
- 67.- Cervantes A, Roselló S, Roda D & Rodríguez-Braun E.
The treatment of advanced gastric cancer: current strategies and future perspectives.
Ann Oncol. 2008 Jul;19 Suppl 5:v103-7
- 68.- Vioque J, Barber X, Bolumar F, Porta M, Santibáñez M, de la Hera MG, Moreno-Osset E; PANESOES Study Group.
Esophageal cancer risk by type of alcohol drinking and smoking: a case-control study in Spain.
BMC Cancer. 2008 Aug 1;8:221.

69.- Cervantes A, Roselló S, Rodríguez-Braun E, Navarro S, Campos S, Hernández A, García-Granero E.

Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer.

Ann Oncol. 2008 Sep;19 Suppl 7:vii266-72.

70.- Cervantes A.

The modern approach to managing locally advanced rectal cancer

Cancer World 2008; 26: 15-20.

71.- Santibáñez M, Vioque J, Alguacil J, Barber X, García de la Hera M, Kauppinen T, for the PANESOES Study Group (entre ellos Cervantes A)

Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain

Occup Environ Med. 2008 Nov;65(11):774-81

72.- Cervantes A.

ECCO 15: 34th ESMO Multidisciplinary Congress in Berlin: a step forward o a high-quality global oncology forum

Clin Transl Oncol. 2009 Oct;11(10):629-30

73.- Cervantes A.

Continuing medical education (CME) or continuing professional development (CPD): a need, a challenge, but also a must

Clin Transl Oncol. 2009 Apr;11(4):189-90

74.- Sabater L; Calvete L; Aparisi L; Cánovas R; Muñoz E; Añón R; Roselló S; Rodríguez E; Camps B; Alfonso R; Sala C; Sastre J; Cervantes A; Lledó S.

Neoplasias de páncreas y periampulares: morbimortalidad, resultados funcionales y supervivencia a largo plazo

Cirugía Espanola 2009; 86-3: 159-166.

75.- Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E.

Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6

76.- García-Granero E; Faiz O; Muñoz E; Flor B; Navarro S; Faus C; García-Botello SA; Lledó S; Cervantes A.

Macroscopic assessment of mesorectal excision in rectal cancer

Cancer. 2009 Aug 1;115(15):3400-11

77.- Chibaudel B; Tournigand C; Artru P; André T; Cervantes A; Figer A; Lledó G; Flesch M; Buyse M; Mineur L; Carola E; Rivera F; Pérez-Staub N; Louvet C; De Gramont A.
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study
Ann Oncol. 2009 Aug;20(8):1383-6

78.- Esclápez P; García-Granero E; Flor B; García-Botello S; Cervantes A; Navarro S; Lledó S.
Prognostic heterogeneity of endosonographic T3 rectal cancer
Dis Colon Rectum. 2009 Apr;52(4):685-91

79.- Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledó G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; De Gramont A.
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
Ann Oncol. 2009 Jun;20(6):1042-7

80.- Pérez-Fidalgo JA; Roda D; Roselló S; Rodríguez-Braun E; Cervantes A.
Aurora kinase inhibitors; a new class of drugs targeting the regulatory mitotic system
Clin Transl Oncol. 2009 Dec;11(12):787-98

81.- Cervantes A.
KRAS: factor predictivo de respuesta en primera línea de tratamiento del cáncer colorrectal metastásico
Revisiones en Cancer 2009; 23-Supl 1: 32-33.

82.- Stahl M, Budach W, Meyer H-J, Cervantes A.
Esophageal cancer: Clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol. 2010 May;21 Suppl 5:v46-9.

83.- Okines A, Verheij M, Allum W, Cunningham D, Cervantes A.
Gastric cancer: ESMO Clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol. 2010 May;21 Suppl 5:v50-4.

84.- Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A.
Primary colon cancer: ESMO Clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol. 2010 May;21 Suppl 5:v70-7.

85.- Balmaña J, Castells A, Cervantes A.
Familial colorectal cancer risk: ESMO Clinical recommendations
Ann Oncol. 2010 May;21 Suppl 5:v78-81.

86.- Glimelius B, Pahlman L, Cervantes A.
Rectal cancer: ESMO Clinical recommendations for diagnosis, treatment and follow up
Ann Oncol. 2010 May;21 Suppl 5:v82-6.

- 87.- Glynne-Jones R, Northover JMA, Cervantes A.
Anal cancer: ESMO Clinical recommendations for diagnosis, treatment and follow up
Ann Oncol. 2010 May;21 Suppl 5:v87-92.
- 88.- Van Cutsem E, Nordlinger B, Cervantes A.
Advanced colorectal cancer: ESMO Clinical recommendations for treatment
Ann Oncol. 2010 May;21 Suppl 5:v93-7.
- 89.- Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group
The burden of rare cancers in Europe
Adv Exp Med Biol. 2010;686:285-303.
- 90.- García-Carbonero R, Gómez España MA, Casado E, Alonso V, Cervantes A, Gallego J, García Alfonso P, Juez I, González Flores E, Lomas M, Isla D.
SEOM clinical guidelines for the treatment of advanced colorectal cancer
Clinical & Translational Oncology. 2010; 11-11: 729-734.
- 91.- Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
Journal of the National Cancer Institute 2010;102 -20: 1547-1556.
- 92.- Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJA, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Colliud S, Oliner KS, Rong A, Gansert J.
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
J Clin Oncol. 2010 Nov 1;28(31):4706-13
- 93.- Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.
Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors
Clin Cancer Res. 2010 Oct 1;16(19):4876-83
- 94.- Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J.
Phase I study of the selective Aurora A Kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics and pharmacodynamics
Mol Cancer Ther. 2010 Oct;9(10):2844-52

- 95.- Roda D, Cervantes A.
Biomarkers in colorectal cancer: the future is getting closer
Clin Transl Oncol. 2010 Apr;12(4):241-2
- 96.- Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodríguez-Braun E, Vega-Villegas ME, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study
Journal of Clinical Oncology 2010: 28-7,1181-1189.
- 97.- Tabernero J, Ciardiello F, Rivera F, Rodríguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A.
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Ann Oncol. 2010 Jul;21(7):1537-45
- 98.- Van Cutsem E; Dicato M; Arber N; Berlin J; Cervantes A; Ciardiello F; De Gramont A; Díaz-Rubio E; Ducreux M; Geva R; Glimelius B; Glynne Joes R; Grothey A; Gruenberger T; Haller D; Haustermans K; Labianca R; Lenz HJ; Minsky B; Nordlinger B; Ohtsu A; Pavlidis N; Rougier P; Schmiegel W; Van de Velde C; Schmoll HJ; Sobrero A; Tabernero J.
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Ann Oncol. 2010 Jun;21 Suppl 6:vi1-10
- 99.- Van Cutsem E; Dicato M; Geva R; Arber N; Bang Y; Benson A; Cervantes A; Díaz-Rubio E; Ducreux M; Glynne-Jones R; Grothey A; Haller D; Haustermans K; Kerr D; Nordlinger B; Marshall J; Minsky BD; Kang YK; Labianca R; Lordick F; Ohtsu A; Pavlidis N; Roth A; Rougier P; Schmoll HJ; Sobrero A; Tabernero J; Van de Velde C; Zalcborg J.
- 100.- The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
Ann Oncol. 2011 Jun;22 Suppl 5:v1-9
- 101.- Pavlidis N; Stahel R; Hansen H; Cervantes A.
Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines
Ann Oncol. 2011 Sep;22 Suppl 6:vi7-11
- 102.- Tabernero J; Dirix L; Schöffski P; Cervantes A; López-Martín JA; Capdevila J; Van Beijsterveldt L; Platero S; Hall B; Yuan Z; Knoblauch R; Zhuang SH.
A phase I first-in-human pharmacokinetic and pharmacodynamic study of Serdemetan in patients with advanced solid tumors
Clin Cancer Res. 2011 Oct 1;17(19):6313-21.

103._ Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro A; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J.

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors

Clin Cancer Res. 2011 Oct 1;17(19):6304-12

104.- García-Granero E; Faiz O; Flor-Lorente B; García-Botello S; Esclápez P; Cervantes A. Prognostic implications of circumferential location of distal rectal cancer

Colorectal Dis. 2011 Jun;13(6):650-7.

105.- Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, O'Neil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrisnan K, Galvin K, Manfredi M, Ecsedy JA.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A Kinase

Cancer Res. 2011 Feb 1;71(3):675-85.

106.- Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giral J; Yuste AL; Antón A; Aranda E.

Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma

Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82

107.- Frasson M; García-Granero E; Roda D; Flor-Lorente B; Roselló S; Esclápez P; Faus C; Navarro S; Campos S; Cervantes A.

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

Cancer. 2011 Jul 15;117(14):3118-25

108.- Cervantes A.

Growth factor receptor-related therapy for gastric cancer

Eur J Cancer. 2011 Sep;47 Suppl 3:S324-5

109.- Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; De Juan A; Redondo A; Martínez S; García Y, Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A.

Feasibility of a modified outpatients regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study

Int J Gynecol Cancer. 2011 Aug;21(6):1048-55

110.- Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; Du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J.

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg)
Int J Gynecol Cancer. 2011 Feb;21(2):419-23.

111.- Dasí F; Navarro-García MM; Jiménez-Heredia M; Magraner J; Viña JR; Pallardó FV; Cervantes A; Morcillo E.

Evaluation of the quality of publications on randomized clinical trials using the Consolidated Standards of Reporting Trials (CONSORT) Statement Guidelines in a Spanish tertiary hospital
J Clin Pharmacol. 2012 Jul;52(7):1106-14

112.- Paz-Ares LG; Gómez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J.

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
J Clin Oncol. 2011 Oct 1;29(28):3783-90

113.- Pérez-Fidalgo JA; Hernández A; Martín V; Cervantes A.

Treatment of cervical cancer: the importance of a multidisciplinary team approach
Clin Transl Oncol. 2011 Jul;13(7):431-3

114.- Gallego J; Cervantes A; Pericay C; Isla D.

SEOM clinical guidelines for the treatment of oesophageal cancer
Clin Transl Oncol. 2011 Aug;13(8):520-4.

115.- Aranda E; Abad A; Carrato A; Cervantes A; García-Foncillas J; García P; García R; Gómez A; Tabernero JM; Díaz-Rubio E.

Treatment recommendations for metastatic colorectal cancer
Clin Transl Oncol. 2011 Mar;13(3):162-78

116.- Pérez-Fidalgo JA; De Stefano A; Roda D; Roselló S; Cervantes A.

Symptom relief with cetuximab for patients with metastatic colorectal cancer
Annals of Gastroenterology & Hepatology 2011: San Lucas Medical,

117.- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

A Phase 3 Trial of Bevacizumab in Ovarian Cancer
N Engl J Med. 2011 Dec 29;365(26):2484-96.

118.- Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group (Cervantes A)
Rare cancers are not so rare: the rare cancer burden in Europe
Eur J Cancer. 2011 Nov;47(17):2493-511.

119.- Faivre J; Trama A; De Angelis R; Elferink M; Siesling S; Audisio R; Bosset JF; Cervantes A; Lepage C; The RARECARE Working Group
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002
Eur J Cancer. 2012 Jul;48(10):1417-24.

120.- Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study.
Oncologist. 2012;17(1):15-25

121.- Pavlidis N, Vermorken JB, Stahel R, Bernier J, Cervantes A, Pentheroudakis G, Audisio RA, Costa A.
Undergraduate training in oncology: An ESO continuing challenge for medical students
Surg Oncol. 2012 Mar;21(1):15-21.

122.- Frasson M, Faus C, Garcia-Granero A, Puga R, Flor-Lorente B, Cervantes A, Navarro S, Garcia-Granero E.
Pathological Evaluation of Mesocolic Resection Quality and Ex Vivo Methylene Blue Injection: What Is the Impact on Lymph Node Harvest After Colon Resection for Cancer?
Dis Colon Rectum. 2012 Feb;55(2):197-204.

123.- Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group.
Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.
Eur J Cancer. 2012 Jan;48(2):159-69.

124.- Pentheroudakis G; Krikelis D; Cervantes A; Vermorken J; Pavlidis N.
Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade.
Cancer Treat Rev. 2012 Oct;38(6):560-5.

125.- Visser O; Adolfsson J; Rossi S; Verne J; Gatta G; Maffezzini M; Franks KN; The RARECARE Working Group
Incidence and survival of rare urogenital cancers in Europe
Eur J Cancer. 2012 Mar;48(4):456-64

126.- Santibáñez M; Alguacil M; de la Hera MG; Navarrete-Muñoz EM; Llorca J; Aragonés N; Kauppinen T; Vioque J; PANESOES Study Group
Occupational exposures and risk of stomach cancer by histological type
Occup Environ Med. 2012 Apr;69(4):268-75.

127.- Mallone S, De Vries E, Guzzo M, Midená E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martínez R, Chirlaque MD, Navarro C, Virgili G; RARECARE WG.
Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe.
Eur J Cancer. 2012 May;48(8):1167-75.

128.- Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I.
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
J Clin Oncol. 2012 May 10;30(14):1620-7.

129.- Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N.
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.
Anticancer Res. 2012 Apr;32(4):1273-81.

130.- Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N.
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.
Clin Exp Metastasis. 2012 Aug;29(6):603-14

131.- Golfopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu T, Marselos M, Fountzilas G, Malamou-Mitsi V, Pavlidis N.
Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.
Ann Oncol. 2012 Oct;23(10):2725-30.

132.- Faivre J; Trama A; De Angelis R; Elferink M; Siesling S; Audisio R; Bosset JF; Cervantes A; Lepage C; RARECARE WG.
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-200
Eur J Cancer. 2012 Jul;48(10):1417-24.

133.- Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrisnan K; Roselló S; Andreu J; Jung JA; Sanchis-García JM; Piera A; Blasco I; Mañós L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J.

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors
Clin Cancer Res. 2012 Sep 1;18(17):4764-74.

134. - Pentheroudakis G; Krikelis D; Cervantes A; Vermorken J; Pavlidis N.

Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade
Cancer Treat Rev. 2012 Oct;38(6):560-5.

135.- Van Dijk BA; Gatta G; Capocaccia R; Pierannunzio D; Strojan P; Licitra L; RARECARE Working Group.

Rare cancers of the head and neck area in Europe.

Eur J Cancer. 2012 Apr;48(6):783-96.

136.- van der Zwan JM; Mallone S; van Dijk B; Bielska-Lasota M; Otter R; Foschi R; Baudin E; Links TP; RARECARE WG.

Carcinoma of endocrine organs: results of the RARECARE project

Eur J Cancer. 2012 Sep;48(13):1923-31.

137.- Schmoll HJ; Van Cutsem E; Stein A; Valentini V; Glimelius B; Haustermans K; Nordlinger B; van de Velde CJ; Balmaña J; Regula J; Nagtegaal ID; Beets-Tan RG; Arnold D; Ciardiello F; Hoff P; Kerr D; Köhne CH; Labianca R; Price T; Scheithauer W; Sobrero A; Tabernero J; Aderka D; Barroso S; Bodoky G; Douillard JY; El Ghazaly H; Gallardo J; Garin A; Glynne-Jones R; Jordan K; Meshcheryakov A; Papamichail D; Pfeiffer P; Souglakos I; Turhal S; Cervantes A.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making.

Ann Oncol. 2012 Oct;23(10):2479-516.

138.- Cervantes A

Preoperative chemotherapy for colon cancer is getting closer.

Lancet Oncol. 2012 Nov;13(11):1073-4.

139.- Garcia-Granero E; Frasson M; Pous S; Cervantes A.

T4a and t4b colorectal cancer: what does this mean nowadays?

Dis Colon Rectum. 2012 Nov;55(11):e367.

140.- Cervantes A; Roda D; Tarazona N; Roselló S; Pérez-Fidalgo JA

Current questions for the treatment of advanced gastric cancer

Cancer Treat Rev. 2013 Feb;39(1):60-7

141.- Díaz-Rubio E; Gómez-España; Massutí B; Sastre J; Reboredo M; Manzano JL; Rivera F; Safont MJ; Montagut C; González E; Benavides M; Marcuello E; Cervantes A; Martínez de Prado P; Fernández-Martos C; Arrivi A; Bando I; Enrique Aranda; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study.

PLoS One. 2012;7(10):e47345

142.- Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN; RARECARE working group (Cervantes A entre ellos)

Incidence and survival of rare urogenital cancers in Europe.

Eur J Cancer. 2012 Mar;48(4):456-64.

143.- Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

Eur J Oncol Nurs. 2012 Dec;16(5):528-34.

144.- Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

Eur J Oncol Nurs. 2012 Dec;16(5):528-34.

145.- Pavlidis N, Stahel R, Pentheroudakis G, Cervantes A; ESMO Guidelines Working Group

ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines.

Ann Oncol. 2012 Oct;23 Suppl 7:vii7-10.

146.- Capdevila J; Cervantes A; Tabernero J.

New players in cancer therapeutics: focus on inhibitors of MDM2-P53 protein-protein interaction

Drugs of the Future 2012; 37-4: 273-281.

147.- Stark D; Nankivell M; Pujade-Lauraine E; Kristensen G; Elit L; Stockler M; Hilpert F; Cervantes A; Brown J; Lancelley A; Velikova G; Sabate E; Pfisterer J; Carey MS; Beale P; Qian W; Swart AM; Oza A; Perren T.

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Lancet Oncol. 2013 Mar;14(3):236-43.

148.- Tabernero J; Shapiro GI; LoRusso PM; Cervantes A; Schwartz GK; Weiss GJ; Paz-Ares L; Cho DC; Infante JR; Alsina M; Gounder MM; Falzone R; Harrop J; White AC; Toudjarska I; Bumcrot D; Meyers RE; Hinkle G; Svrzikapa N; Hutabarat RM; Clausen VA; Cehelsky J; Nochur SV; Gamba-Vitalo C; Vaishnav AK; Sah DW; Gollob JA; Burris HA 3rd. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Cancer Discov. 2013 Apr;3(4):406-17.

149.- Pérez-Fidalgo JA; Cervantes A.

Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.

Ann Oncol. 2013 Apr;24(4):1129-30.

150.- González Martín A; Redondo A; Jurado M; De Juan A; Romero I; Bover I; Del Campo JM; Cervantes A; García Y; López-Guerrero JA; Mendiola C; Palacios J; Rubio MJ; Poveda Velasco A

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

Clin Transl Oncol. 2013 Jul;15(7):509-25.

151.- Van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borrás JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Pålman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmolli HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V.

EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe.

Eur J Cancer. 2013 Sep;49(13):2784-90.

152.- Balmaña J; Balaguer F; Cervantes A; Arnold D; ESMO Guidelines Working Group.

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.

Ann Oncol. 2013 Oct;24 Suppl 6:vi73-80.

153.- Yan Y; Serra V; Prudkin L; Scaltriti M; Murli S; Rodriguez O; Guzman M; Sampath D; Nannini M; Xiao Y; Wagle MC; Wu J; Hampton GM; Wongchenko M; Ramakrishnan V; Lackner MR; Saura C; Roda D; Cervantes A; Tabernero J; Patel P; Baselga J

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res. 2013 Dec 15;19(24):6976-86.

154.- Stahl M; Mariette C; Haustermans K; Cervantes A; Arnold D; ESMO Guidelines Working Group.

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi51-6.

155.- Waddell T; Verheij M; Allum W; Cunningham D; Cervantes A; Arnold D.

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi57-63.

156.- Labianca R; Nordlinger B; Beretta GD; Mosconi S; Mandalà M; Cervantes A; Arnold D; ESMO Guidelines Working Group.

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72.

157.- Glimelius B; Tiret E; Cervantes A; Arnold D; ESMO Guidelines Working Group.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi81-8.

158.- Scalfani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Ann Oncol. 2013 Dec;24(12):3123-8.

159.- Van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T; RARECARE WG

Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project.

Eur J Cancer. 2013 Jul;49(11):2565-78.

160.- Gonzalez-Martin A, Gladiëff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.

Eur J Cancer. 2013 Dec;49(18):3831-8.

161.- Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia R; RARECARE WG.

Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project.

Cancer Epidemiol. 2013 Dec;37(6):850-6.

162.- van de Velde CJ; Boelens PG; Borrás JM; Coebergh JW; Cervantes A; Blomqvist L; Beets-Tan RG; van den Broek CB; Brown G; Van Cutsem E; Espin E; Haustermans K; Glimelius B; Iversen LH; van Krieken JH; Marijnen CA; Henning G; Gore-Booth J; Meldolesi E; Mroczkowski P; Nagtegaal I; Naredi P; Ortiz H; Pålman L; Quirke P; Rödel C; Roth A; Rutten H; Schmoll HJ; Smith JJ; Tanis PJ; Taylor C; Wibe A; Wiggers T; Gambacorta MA; Aristei C; Valentini V.

EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum.

Eur J Cancer. 2014 Jan;50(1):1.e1-1.e34.

163.- Delord JP; Tabernero J; García-Carbonero R; Cervantes A; Gomez-Roca C; Bergé Y; Capdevila J; Paz-Ares L; Roda D; Delmar P; Oppenheim D; Brossard SS; Farzaneh F; Manenti L; Passiukov A; Ott MG; Soria JC.

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.

Eur J Cancer. 2014 Feb;50(3):496-505.

164.- Stoyianni A; Pentheroudakis G; Benjamin H; Cervantes A; Ashkenazi K; Lazaridis G; Pavlidis N; Spector Y.

Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.

Clin Transl Oncol. 2014 Aug;16(8):725-31.

165.- Popescu RA; Schäfer R; Califano R; Eckert R; Coleman R; Douillard JY; Cervantes A; Casali PG; Sessa C; Van Cutsem E; de Vries E; Pavlidis N; Fumasoli K; Wörmann B; Samonigg H; Cascinu S; Cruz Hernández JJ; Howard AJ; Ciardiello F; Stahel RA; Piccart M. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

Ann Oncol. 2014 Jan;25(1):9-15.

166.- Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tian Y; Sidhu R.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

Ann Oncol. 2014 Jan;25(1):107-16.

167.- Waddell T; Verheij M; Allum W; Cunningham D; Cervantes A; Arnold D.

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Radiother Oncol. 2014 Jan;110(1):189-94.

168.- Lordick F; Allum W; Carneiro F; Mitry E; Tabernero J; Tan P; Van Cutsem E; van de Velde C; Cervantes A.

Unmet needs and challenges in gastric cancer: the way forward.

Cancer Treat Rev. 2014 Jul;40(6):692-700.

169.- Breugom AJ; Boelens PG; van den Broek CB; Cervantes A; Van Cutsem E; Schmoll HJ; Valentini V; van de Velde CJ.

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative.

Ann Oncol. 2014 Aug;25(8):1485-92.

170.- Garcia-Carbonero R; Rivera F; Maurel J; Ayoub JP; Moore MJ; Cervantes A; Asmis TR; Schwartz JD; Nasroulah F; Ballal S; Tabernero J.

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

Oncologist. 2014 Apr;19(4):350-1.

171.- Waddell T; Verheij M; Allum W; Cunningham D; Cervantes A; Arnold D; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO).

Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Radiother Oncol. 2014 Jan;110(1):189-94.

172.- Cervantes A

Exploring better strategies for EGFR antibodies in colon cancer.

Lancet Oncol. 2014 May; 15(6):549-50.

173.- Sabater L; Gómez-Mateo MD; López-Sebastián J; Muñoz-Forner E; Morera-Ocón F; Cervantes A; Roselló S; Camps-Vilata B; Ferrández A; Ortega J.

Prognostic implications of the standardized study of resection margins in pancreatic cancers.

Cir Esp. 2014 Oct; 92(8):532-8

174.- Glynne-Jones R; Nilsson PJ; Aschele C; Goh V; Peiffert D; Cervantes A; Arnold D.

Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Eur J Surg Oncol. 2014 Oct; 40(10):1165-76

175.- Ciardiello F; Arnold D; Casali PG; Cervantes A; Douillard JY; Eggermont A; Eniu A; McGregor K; Peters S; Piccart M; Popescu R; Van Cutsem E; Zielinski C; Stahel R.

Delivering Precision Medicine in Oncology Today and in Future-The Promise and Challenges of Personalised Cancer Medicine: a position paper by the European Society for Medical Oncology (ESMO).

Ann Oncol. 2014 Sep; 25(9):1673-8.

176.- Coleman R; Body JJ; Aapro M; Hadji P; Herrstedt J; ESMO Guidelines Working Group

Bone health in cancer patients: ESMO Clinical Practice Guidelines.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii124-37.

177.- Stupp R; Brada M; van den Bent MJ; Tonn JC; Pentheroudakis G; ESMO Guidelines Working Group.

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii93-101.

178.- Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C; PETACC-8 Study Investigators.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Lancet Oncol. 2014 Jul; 15(8):862-73.

179.- Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Tabernero J; Glimelius B; Cervantes A; Dewdney A; Wotherspoon A; Brown G; Tait D; Oates J; Chau I. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

J Natl Cancer Inst. 2014 Jun 23; 106(7)

180.- Sehouli J; Pietzner K; Wimberger P; Vergote I; Rosenberg P; Schneeweiss A; Bokemeyer C; Salat C; Scambia G; Berton-Rigaud D; Santoro A; Cervantes A; Trédan O; Tournigand C; Colombo N; Dudnichenko AS; Westermann A; Friccius-Quecke H; Lordick F.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Med Oncol. 2014 Aug; 31(8):76.

181.- Pentheroudakis G; Kotteas EA; Kotoula V; Papadopoulou K; Charalambous E; Cervantes A; Ciuleanu T; Fountzilas G; Pavlidis N.

Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group

Clin Exp Metastasis. 2014 Oct; 31(7):761-9.

182.- Glynne-Jones R; Nilsson PJ; Aschele C; Goh V; Peiffert D; Cervantes A; Arnold D

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Radiother Oncol. 2014 Jun; 111(3):330-9.

183.- Bellmunt J; Orsola A; Leow JJ; Wiegel T; De Santis M; Horwich A; ESMO Guidelines Working Group

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii40-8.

184.- Reck M; Popat S; Reinmuth N; De Ruyscher D; Kerr KM; Peters S; ESMO Guidelines Working Group.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii27-39.

185.- Dreyling M; Ghilmini M; Marcus R; Salles G; Vitolo U; Ladetto M; ESMO Guidelines Working Group.

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii76-82.

186.- Fenaux P; Haase D; Sanz GF; Santini V; Buske C; ESMO Guidelines Working Group.

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii57-69.

187.- Eichenauer DA; Engert A; André M; Federico M; Illidge T; Hutchings M; Ladetto M; ESMO Guidelines Working Group.

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii70-5.

188.- Van Cutsem E; Cervantes A; Nordlinger B; Arnold D; ESMO Guidelines Working Group.

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii1-9.

189.- Schrijvers D; Cherny NI; ESMO Guidelines Working Group

ESMO Clinical Practice Guidelines on palliative care: advanced care planning.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii138-42.

190.- Cherny NI; ESMO Guidelines Working Group.

ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii143-52.

191.- Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A; ESMO Guidelines Working Group.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii49-56.

192.- Dreyling M; Geisler C; Hermine O; Kluin-Nelemans HC; Le Gouill S; Rule S; Shpilberg O; Walewski J; Ladetto M; ESMO Guidelines Working Group

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii83-92.

193.- Glynn-Jones R; Nilsson PJ; Aschele C; Goh V; Peiffert D; Cervantes A; Arnold D

Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep; 25 Suppl 3:iii10-20.

194.- DiCosimo S; Sathyanarayanan S; Bendell JC; Cervantes A; Stein MN; Brana I; Roda Perez D; Haines B; Zhang T; Winter C; Jha S; Xu Y; Frazier J; Klinghofer R; Leighton-Swayze A; Song Y; Ebbinghaus S; Baselga J.

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Clin Cancer Res. 2015 Jan 1; 21(1):49-59.

195.- Geva R; Vecchione L; Kalogeras KT; Vittrup Jensen B; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilias G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Gut. 2015 Jun; 64(6):921-8.

196._Cervantes A; Glynne-Jones R.

Adjuvant Chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all.

Ann Oncol. 2015 Apr; 26(4):617-9.

197.- Cervantes A; Pentheroudakis G; Arnold D.

Critical evaluation of the scientific content in clinical practice guidelines.

Cancer. 2015 Jun 1; 121(11):1907-8.

198.- Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E.

Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.

Dis Colon Rectum. 2015 Jun; 58(6):556-65.

199.- Dienstmann R; Patnaik A; Garcia-Carbonero R; Cervantes A; Benavent M; Roselló S; Tops BB; van der Post RS; Argilés G; Skartved NJ; Hansen UH; Hald R; Pedersen MW; Kragh M; Horak ID; Braun S; Van Cutsem E; Tolcher AW; Tabernero J.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Cancer Discov. 2015 Jun; 5(6):598-609.

200.- Dienstmann R; Cervantes A.

Heterogeneity of driver genes and therapeutic implications in colorectal cancer.

Ann Oncol. 2015 Aug; 26(8):1523-5.

201.- Mayer RJ; Van Cutsem E; Falcone A; Yoshino T; Garcia-Carbonero R; Mizunuma N; Yamazaki K; Shimada Y; Tabernero J; Komatsu Y; Sobrero A; Boucher E; Peeters M; Tran B; Lenz HJ; Zaniboni A; Hochster H; Cleary JM; Prenen H; Benedetti F; Mizuguchi H; Makris L; Ito M; Ohtsu A; RECURSE Study Group.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

N Engl J Med. 2015 May 14; 372(20):1909-19.

202.- Macarulla T; Cervantes A; Tabernero J; Roselló S; Van Cutsem E; Tejpar S; Prenen H; Martinelli E; Troiani T; Laffranchi B; Jego V; von Richter O; Ciardiello F.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Br J Cancer. 2015 Jun 9; 112(12):1874-81.

203.- Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR Jr; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. *Clin Cancer Res.* 2015 Jun 1; 21(11):2462-70.

204.- Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ; ICON7 trial investigators.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Lancet Oncol. 2015 Aug; 16(8):928-36.

205.- Scialfani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Ann Oncol. 2015 Sep; 26(9):1936-41.

206.- Roselló S; Cervantes A

Extending neoadjuvant chemotherapy in rectal cancer.

Lancet Oncol. 2015 Aug; 16(8):880-1.

207.- Pentheroudakis G; Cardoso F; Arnold D; Sessa C; Peters S; Horwich A; Pavlidis N; Stahel R; Cervantes A; ESMO Guidelines Committee.

The ESMO guideline strategy: an identity statement and reflections on improvement.

Ann Oncol. 2015 Sep; 26 Suppl 5:v1-7.

208.- Peeters M; Oliner K; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; Andre T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD.

Analysis of KRAS/NRAS Mutations in a Phase 3 Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone as Second-Line Treatment for Metastatic Colorectal Cancer.

Clin Cancer Res. 2015 Dec 15; 21(24):5469-79.

209.- Ibarrola-Villava M; Llorca-Cardenosa MJ; Tarazona N; Mongort C; Fleitas T; Perez-Fidalgo JA; Roselló S; Navarro S; Ribas G; Cervantes A.

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.

Oncotarget. 2015 Sep 29; 6(29):26935-45.

210.- Tarazona N; Navarro L; Cejalvo JM; Gambardella V; Pérez-Fidalgo JA; Sempere A; Navarro S; Cervantes A.

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.

Onco Targets Ther. 2015 May 14; 8:1053-9.

211.- Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Zaragoza R; Cervantes A

EGF-induced Acetylation of Heterogeneous nuclear ribonucleoproteins is dependent on KRAS mutational status in colorectal cancer cells

PLoS One. 2015 Jun 25; 10(6):e0130543.

212.- Baas P; Fennell D; Kerr KM; Van Schil PE; Haas RL; Peters S; ESMO Guidelines Committee.

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v31-9.

213.- Vannucchi AM; Barbui T; Cervantes F; Harrison C; Kiladjian JJ; Kröger N; Thiele J; Buske C; ESMO Guidelines Committee.

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep;26 Suppl 5:v85-99.

214.- Robak T; Matutes E; Catovsky D; Zinzani PL; Buske C; ESMO Guidelines Committee
Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v100-7.

215.- d'Amore F; Gaulard P; Trümper L; Corradini P; Kim WS; Specht L; Bjerregaard Pedersen M; Ladetto M; ESMO Guidelines Committee.

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v108-15.

216.- Tilly H; Gomes da Silva M; Vitolo U; Jack A; Meignan M; Lopez-Guillermo A; Walewski J; André M; Johnson PW; Pfreundschuh M; Ladetto M; ESMO Guidelines Committee.

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v116-25.

217.- Dummer R; Hauschild A; Lindenblatt N; Pentheroudakis G; Keilholz U; ESMO Guidelines Committee.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v126-32.

218.- Fizazi K; Greco FA; Pavlidis N; Daugaard G; Oien K; Pentheroudakis G; ESMO Guidelines Committee.

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v133-8

219.- Sousa B; Furlanetto J; Hutka M; Gouveia P; Wuerstlein R; Mariz JM; Pinto D; Cardoso F; ESMO Guidelines Committee.

Central venous access in oncology: ESMO Clinical Practice Guidelines.

Ann Oncol. 2015 Sep; 26 Suppl 5:v152-68.

220.- Kloke M, Cherny N; ESMO Guidelines Committee.

Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines.

Ann Oncol. 2015 Sep; 26 Suppl 5:v169-73.

221.- Girard N; Ruffini E; Marx A; Faivre-Finn C; Peters S; ESMO Guidelines Committee
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v40-55.

222.- Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee.

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v78-84.

223.- Senkus E; Kyriakides S; Ohno S; Penault-Llorca F; Poortmans P; Rutgers E; Zackrisson S; Cardoso F; ESMO Guidelines Committee.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v8-30.

224.- Peterson DE; Boers-Doets CB; Bensadoun RJ; Herrstedt J; ESMO Guidelines Committee.

Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v139-51.

225.- Parker C; Gillessen S; Heidenreich A; Horwich A; ESMO Guidelines Committee.

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v69-77.

226.- Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2015 Sep; 26 Suppl 5:v56-68.

227.- Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG); the European Organization for Research and Treatment of Cancer¿Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario (GEICO).

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.

Support Care Cancer. 2016 Mar; 24(3):1241-9.

228.- Meulendijks D; Jacob W; Martinez-Garcia M; Taus A; Lolkema M; Voest E; Langenberg MH; Fleitas T; Cervantes A; de Jonge MJ; Sleijfer S; Mau-Sørensen M; Thomas M; Ceppi M; Meneses-Lorente G; James I; Adessi C; Michielin F; Abiraj K; Bossenmaier B; Schellens JH; Weisser M; Lassen U.

First-in-human phase I study of Lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER-3 positive solid tumors.

Clin Cancer Res. 2016 Feb 15; 22(4):877-85.

229.- Cherny NI; Kloke M; Cervantes A; Pentheroudakis G; ESMO Guidelines Committee Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.

Ann Oncol. 2016 Mar;27(3):550-1.

230.- Elez E; Hendlisz H; Delaunoit T; Sastre J; Cervantes A; Varea R; Chao G; Wallin J; Tabernero J.

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.

Br J Cancer. 2016 Feb 16; 114(4):372-80.

231.- Gambardella V; Tarazona N; Cejalvo JM; Roselló S; A Cervantes

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.

Expert Opin Drug Metab Toxicol. 2016; 12(4):449-56.

232.- Ibarrola-Villava M; Fleitas T; Llorca-Cardenosa MJ; Mongort C; Alonso E; Navarro S; Burgues O; Vivancos A; Cejalvo JM; Perez-Fidalgo JA; Roselló S; Ribas G; Cervantes A. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Oncotarget. 2016 Apr 19; 7(16):22543-55.

233.- Roselló S; Cervantes A.

Non-surgical treatment of localized rectal cancer is an experimental option.

Cir Esp. 2016 Jun-Jul; 94(6):311-2.

234.- Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A.

Personalised Treatment in Gastric Cancer: Myth or Reality?

Curr Oncol Rep. 2016 Jul; 18(7):41.

235.- Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I.

PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Ann Oncol. 2016 Aug; 27(8):1557-65.

236.- Breugom AJ; Bastiaannet E; Boelens PG; Iversen LH; Martling A; Johansson R; Evans T; Lawton S; O'Brien KM; Van Eycken E; Janciauskiene R; Liefers GJ; Cervantes A; Lemmens VE; van de Velde CJ

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.

Eur J Cancer. 2016 Aug; 63:110-7.

237.- Gruenberger T; Beets G; Van Laethem JL; Rougier P; Cervantes A; Douillard JY; Figueras J; Gruenberger B; Haller DG; Labianca R; Maleux G; Roth A; Ducreux M; Schmiegel W; Seufferlein T; Van Cutsem E.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Dig Liver Dis. 2016 Oct; 48(10):1119-23.

238.- Van Cutsem E; Cervantes A; Adam R; Sobrero A; Van Krieken JH; Aderka D; Aranda Aguilar E; Bardelli A; Benson A; Bodoky G; Ciardiello F; D'Hoore A; Diaz-Rubio E; Douillard JY; Ducreux M; Falcone A; Grothey A; Gruenberger T; Haustermans K; Heinemann V; Hoff P; Köhne CH; Labianca R; Laurent-Puig P; Ma B; (238).- Maughan T; Muro K; Normanno N; Österlund P; Oyen WJ; Papamichael D; Pentheroudakis G; Pfeiffer P; Price TJ; Punt C; Ricke J; Roth A; Salazar R; Scheithauer W; Schmoll HJ; Tabernero J; Taïeb J; Tejpar S; Wasan H; Yoshino T; Zaanan A; Arnold D.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Ann Oncol. 2016 Aug;27(8):1386-422.

239.- Ditttrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz JP; Österlund P; Pavlidis N; Purkalne G; ESMO/ASCO Global Curriculum Working Group.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Ann Oncol. 2016 Aug; 27(8):1378-81.

- 240.- Fleitas T; Ibarrola-Villava M; Ribas G; Cervantes A.
MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.
Cancer Treat Rev. 2016 Sep; 49:57-64.
- 241.- Sciafani F; Chau I; Cunningham D; Lampis A; Hahne JC; Ghidini M; Lote H; Zito D; Taberero J; Glimelius B; Cervantes A; Begum R; De Castro DG; Wilson SH; Peckitt C; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Braconi C; Valeri N.
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Carcinogenesis. 2016 Sep;37(9):852-7.
- 242.- Llorca-Cardena MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.
Oncotarget. 2016 Sep 27;7(39):63424-63436.
- 243.- Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A.
Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Breast Cancer Res Treat. 2016 Nov; 160(1):69-77.
- 244.- Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T.
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.
Dig Liver Dis. 2016 Nov; 48(11):1283-1289.
- 245.- Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee..
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49.
- 246.- Riffo-Campos AL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L.
In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Oncol Rep. 2016 Dec; 36(6):3627-3634.

247.- Morgan G; Lambertini M; Kourie HR; Amaral T; Argiles G; Banerjee S; Cardone C; Corral J; De Mattos-Arruda L; Öztürk A; Petrova M; Poulsen L; Strijbos M; Tyulyandina A; Vidra R; Califano R; de Azambuja E; Garrido Lopez P; Guarneri V; Reck M; Moiseyenko V; Martinelli E; Douillard JY; Stahel R; Voest E; Arnold D; Cardoso F; Casali P; Cervantes A; Eggermont AM; Eniu A; Jassem J; Pentheroudakis G; Peters S; McGregor K; Rauh S; Zielinski CC; Ciardiello F; Tabernero J; Preusser M.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

ESMO Open. 2016 Dec 7; 1(6):e000107

248.- Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A.

A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors.

Cancer Discov. 2017 Jan; 7(1):102-113.

249.- Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R.

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECURSE trial.

Clin Transl Oncol. 2017 Feb; 19(2):227-235.

250.- Flor-Lorente B; Báguena G; Frasson M; García-Granero A; Cervantes A; Sanchiz V; Peña A; Espí A; Esclapez P; García-Granero E.

Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results.

Cir Esp. 2017 Mar;95(3):143-151.

251.- Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

PLoS One. 2017 May 11; 12(5):e0177331.

252.- Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Ann Oncol. 2017 Aug 1; 28(8):1713-1729.

253.- Lieu CH; Hidalgo M; Berlin JD; Ko AH; Cervantes A; LoRusso P; Gerber DE; Eder JP; Eckhardt SG; Kapp AV; Tshako A; McCall B; Pirzkall A; Uyei A; Tabernero J.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Oncologist. 2017 Sep; 22(9):1024-e89

254.- Meulendijks D; Jacob W; Voest EE; Mau-Sorensen M; Martinez-Garcia M; Taus A; Fleitas T; Cervantes A; Lolkema MP; Langenberg MHG; De Jonge MJ; Sleijfer S; Han JY; Calles A; Filip E; Kim SW; Schellens JHM; Wilson S; Thomas M; Ceppi M; Meneses-Lorente G; James I; Vega-Harrington S; Dua R; Nguyen M; Steiner L; Adessi C; Michielin F; Bossenmaier B; Weisser M; Lassen UN

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Clin Cancer Res. 2017 Sep 15; 23(18):5406-5415.

255.- Emile JF; Julié C; Le Malicot K; Lepage C; Taberero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSCG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigaçã Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Eur J Cancer. 2017 Sep; 82: 16-24.

256.- Taberero J; Vyas M; Giuliani R; Arnold D; Cardoso F; Casali PG; Cervantes A; Eggermont AM; Eniu A; Jassem J; Pentheroudakis G; Peters S; Rauh S; Zielinski CC; Stahel RA; Voest E; Douillard JY; McGregor K; Ciardiello F.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

ESMO Open. 2017 Jan 16;1(6):e000142.

257.- Roselló S; Blasco I; García Fabregat L; Cervantes A; Jordan K; ESMO Guidelines Committee.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Ann Oncol. 2017 Jul 1; 28(suppl_4):iv100-iv118.

258.- Glynne-Jones R; Wyrwicz L; Tiret E; Brown G; Rödel C; Cervantes A; Arnold D; ESMO Guidelines Committee.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2017 Jul 1; 28(suppl_4):iv22-iv40.

259.- **Cervantes A**, Terol MJ.

In the literature: February 2017.

ESMO Open. 2017 Mar 24;2(1):e000171

260. **Cervantes A**

In the literature: April 2017.

ESMO Open. 2017 May 2;2(2):e000193

261.- Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, **Cervantes A**, Arnold D;
ESMO Guidelines Committee.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40

262.- García-García AB, Gómez-Mateo MC, Hilario R, Rentero-Garrido P, Martínez-Domenech A, Gonzalez-Albert V, **Cervantes A**, Marín-García P, Chaves FJ, Ferrández-Izquierdo A, Sabater L.

mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival.

Oncotarget. 2017 Aug 3;8(62):104796-104805

263.- Grothey A, Shah M, Yoshino T, Van Cutsem E, Taieb J, Xu R, Tebbutt NC, Falcone A, **Cervantes A**; other CanStem303 Investigators, Borodyansky L, Li CJ.

Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer.

Ann Oncol. 2017 Jun 1;28(suppl_3)

264.- Tarazona N, **Cervantes A**.

Liquid biopsy: another tool towards tailored therapy in colorectal cancer.

Ann Oncol. 2018 Jan 1;29(1):7-8.

265.- Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, **Cervantes A**, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Ann Oncol. 2018 Jan 1;29(1):44-70

266.- Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, **Cervantes A**.

Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.

Clin Colorectal Cancer. 2018 Jun;17(2):104-112.e2

267.- Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, **Cervantes A**.

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.

Ann Oncol. 2018 Jan 1;29(1):36-43.

268.- Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, **Cervantes A**.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Invest New Drugs. 2018 Oct;36(5):848-859

269.- Roselló S, Papaccio F, Roda D, Tarazona N, **Cervantes A**.

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.

Cancer Treat Rev. 2018 Feb;63:156-171.

270.- Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, André T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, **Cervantes A**.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Ann Oncol. 2018 May 1;29(5):1099-1107

271.- **Cervantes A**.

In the literature: February 2018.

ESMO Open. 2018 Feb 1;3(2):e000322.

272. Telechea-Fernández M, Rodríguez-Fernández L, García C, Zaragozá R, Viña J, **Cervantes A**, García-Trevijano ER.

New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.

Oncotarget. 2018 Jan 3;9(10):9100-9113

273.- Gambardella V, **Cervantes A**.

Precision medicine in the adjuvant treatment of gastric cancer.

Lancet Oncol. 2018 May;19(5):583-584.

274.- Gambardella V, Bruixola G, **Cervantes A**.

In the literature: April 2018.

ESMO Open. 2018 Apr 13;3(3):e000362

275.- Peeters M, **Cervantes A**, Moreno Vera S, Taieb J.

Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.

Future Oncol. 2018 Jul;14(16):1629-1645.

276.- Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, **Cervantes A**, Arnold D; ESMO Guidelines Committee.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Supplement_4):iv263.

277.- Roselló S, Blasco I, García Fabregat L, **Cervantes A**, Jordan K; ESMO Guidelines Committee.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv260.

278.- Riffo-Campos ÁL, Gimeno-Valiente F, Rodríguez FM, **Cervantes A**, López-Rodas G, Franco L, Castillo J.

Role of epigenetic factors in the selection of the alternative splicing isoforms of human *KRAS* in colorectal cancer cell lines.

Oncotarget. 2018 Apr 17;9(29):20578-20589

279.- Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points.

Roselló S, **Cervantes A**.

Ann Oncol. 2018 Jul 1;29(7):1493-1494

280.- Dickler MN, Saura C, Richards DA, Krop IE, **Cervantes A**, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387

281.- Patel UB, **Cervantes A**, Fernández-Martos C, Sclafani F, Cunningham D, Nilsson P, Brown G.

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

Colorectal Dis. 2018 May;20 Suppl 1:56-60

282.- Roda D, Ciardiello F, **Cervantes A**

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?

ESMO Open. 2018 Jun 20;3(4):e000392.

283.- Pérez-Fidalgo JA, Gambardella V, **Cervantes A**.

In the literature: June 2018.

ESMO Open. 2018 Jun 20;3(4):e000401.

284.- Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, **Cervantes A**.

Borderline resectable pancreatic cancer. Challenges and controversies.

Cancer Treat Rev. 2018 Jul;68:124-135

285.- Ibarrola-Villava M, **Cervantes A**, Bardelli A.

Preclinical models for precision oncology.

Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):239-246.

286.- Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, **Cervantes A**, Ciardiello F, De Vita F.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868.

287. Normanno N, **Cervantes A**, Ciardiello F, De Luca A, Pinto C.

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

Cancer Treat Rev. 2018 Nov;70:1-8

288.- Elez E, Quintanar T, Bosch-Barrera J, Corral J, Lainez N, Moreno V, Rodriguez CA, Gonzalez-Flores E, **Cervantes A**.

The Medical Oncology resident mentor: situation and workload.

Clin Transl Oncol. 2019 Mar;21(3):304-313

289.- Smyth EC, **Cervantes A**.

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed.

Ann Oncol. 2018 Oct 1;29(10):2027-2028.

290.- Gambardella V, Martin-Martorell P, **Cervantes A**.

In the literature: August 2018.

ESMO Open. 2018 Aug 31;3(6):e000427

291.- Vogel A, **Cervantes A**, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv238-iv255

292.- Kaasa S, Loge JH, Aapro M, Albrecht T, Anderson R, Bruera E, Brunelli C, Caraceni A, **Cervantes A**, Currow DC, Deliens L, Fallon M, Gómez-Batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjerstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundebj T.

Integration of oncology and palliative care: a Lancet Oncology Commission.

Lancet Oncol. 2018 Nov;19(11):e588-e653

293.- Stiefel F, Kiss A, Salmon P, Peters S, Razavi D, **Cervantes A**, Margulies A, Bourquin C; participants .

Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018.

Ann Oncol. 2018 Oct 1;29(10):2033-2036

294. Roda D, Gambardella V, **Cervantes A**.

In the literature: October 2018.

ESMO Open. 2018 Oct 11;3(6):e000447

295.- Bruixola G, Caballero J, Papaccio F, Petrillo A, Iranzo A, Civera M, Moriana M, Bosch N, Maroñas M, González I, Pastor M, **Cervantes A**.

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

ESMO Open. 2018 Oct 24;3(6):e000425

296.- Roselló S, Borrás R, **Cervantes A**.

Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):395-398

297.- Gambardella V, Fleitas T, **Cervantes A**.

In the literature: December 2018.

ESMO Open. 2018 Nov 28;3(7):e000468.

298.- González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, **Cervantes A**, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators.

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

Gynecol Oncol. 2019 Jan;152(1):53-60.

299.- Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, **Cervantes A**.

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression.

Mod Pathol. 2019 Feb;32(2):306-313.

300.- Gambardella V, Gimeno-Valiente F, Tarazona N, Ciarpaglini CM, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, **Cervantes A**.

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in *HER2*-Amplified Gastric Cancer.

Clin Cancer Res. 2019 Mar 1;25(5):1639-1649

301.- Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, García P, Aranda E, Elez E, López-López R, **Cervantes A**, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Combination of KIR2DS4 and FcγRIIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Sci Rep. 2019 Feb 22;9(1):2589

302.- Costas-Chavarri A, Nandakumar G, Temin S, Lopes G, **Cervantes A**, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Huitzil FD, Malekzadeh Moghani M, Sharara AI, Stern MC, Teh C, Vázquez Manjarrez SE, Verjee A, Yantiss R, Shah MA.

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.

J Glob Oncol. 2019 Feb;5:1-19

303.- Lopes G, Stern MC, Temin S, Sharara AI, **Cervantes A**, Costas-Chavarri A, Engineer R, Hamashima C, Ho GF, Huitzil FD, Moghani MM, Nandakumar G, Shah MA, Teh C, Manjarrez SEV, Verjee A, Yantiss R, Correa MC.

Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline.

J Glob Oncol. 2019 Feb;5:1-22

304.- Gambardella V, Tleitas T, **Cervantes A**.

Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer.

Ann Oncol. 2019 Jan 18. doi: 10.1093/annonc/mdz008. [Epub ahead of print]

305.- Vogel A, **Cervantes A**, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2019 Jan 31. doi: 10.1093/annonc/mdy510. [Epub ahead of print]

306.- Jung KH, LoRusso PM, Burris HA, Gordon MS, Bang YJ, Hellmann MD, **Cervantes A**, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott DF, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tshako A, Morrissey KM, Mahrus S, Morley R, Pirzkall A, Davis SL.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Clin Cancer Res. 2019 Feb 15. pii: clincanres.2740.2018. [Epub ahead of print]

307.- Fontana E, Eason K, **Cervantes A**, Salazar R, Sadanandam A.

Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials.

Ann Oncol. 2019 Feb 23. pii: mdz052. [Epub ahead of print]

308.- Baguena G, Pellino G, Frasson M, Roselló S, **Cervantes A**, García-Granero A, Giner F, García-Granero E.

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. Dis Colon Rectum. 2019 Mar 4. [Epub ahead of print]

H-index on March 12, 2019, according to Google Scholar: 70, number of citations: 26.157, number of citations since 2014: 14.858

H-index on March 12, 2019, according to Scopus: 59, number of publications: 264, number of citations: 14.859

H-index on March 13, 2019, according to Web of Science: 66, number of citations: 20.450

Book Chapters

1.- Cervantes A, Chirivella I. (2006) "Tumores del estomago", in Abad A, Gascón P, Díaz Rubio E (eds.) *Guía práctica de tumores solidos*. Madrid: Tactics MD, S.L., pp: 113-117

2.- Cervantes A, Rodríguez B, Pérez Fidalgo A, Bosch A, Roselló S, Chirivella I. (2007) *Manuales Prácticos. Oncología. Cáncer gástrico*. Madrid: Arán Ediciones S.L.

3.- Cervantes A. (ed) (2008) *International Oncology Updates. New treatments for ovarian cancer*. Barcelona: Publicaciones Permanyer.

Author of the following chapter in this book:

4.- Cervantes A, Roselló S y Rodríguez E. (2008) "Antiangiogenic drugs in ovarian cancer", pp: 91-98.

5.- Cervantes A, Insa A, Chirivella I, Roselló S, Escrig V (2008) "La quimioterapia en los cánceres de cabeza y cuello", in Suárez Nieto C, Gil-Carcedo García LM, Marco Algarra J, Medina JE, Ortega del Álamo P, Trinidad Pinedo J (eds) *Tratado de otorrinolaringología y cirugía de cabeza y cuello*. Madrid: Médica Panamericana, pp: 135-143

6.- Cervantes A, Chirivella I. (2009) "Tumores del estómago" in Abad A, Gascón P, Díaz Rubio E (eds) *Guía práctica de tumores sólidos*. Madrid: Tactics MD, S.L, pp: 115-120

7.- Pallardó Y, Cervantes A, Revert AJ. (2009) "Estadificación del cáncer y valoración de la respuesta al tratamiento" in Pallardó Y, Revert AJ, Cervera J (eds) *Actualizaciones SERAM. Imagen en Oncología*. Madrid: Médica Panamericana, pp: 1-12

8.- Cervantes A, Rodríguez-Braun E, Roda D, Roselló S (eds) (2009) *Ovarian Cancer Reports. ASCO 2009. 45th American Society of Clinical Oncology (ASCO) Annual Meeting*. Barcelona: Publicaciones Permanyer.

9.- Lluch A, Cervantes A (coordinators) (2009) *Highlights from ASCO 2009. Cáncer de mama y cáncer de ovario*. Barcelona: Publicaciones Permanyer.

10.- Cervantes A, Roselló S, Rodríguez-Braun E (2009) "Cáncer de recto" in Abad Esteve A, Lluch Hernández A, Martín Jiménez M, Mendiola Fernández C (eds) *Protocolos en Oncología*. Madrid: You & Us, S.A, pp: 267-276

11.- Cervantes A, Roselló S, Rodríguez Braun E, Roda D (2010) "Cáncer gástrico" in González Barón M (ed) *Oncología Clínica, vol. 2*. Madrid: Momento Médico Iberoamericana S.L.

12.- Tortora G, Bergmann L, Lindh MB, Cervantes A, Dziadziuszko R, Eckhardt SG, Lenz HJ, Normanno N, Roda D, Scarpa A, Syrigos K, Tabernero J, Troiani T (eds) (2012). *ESMO Glossary in Molecular Biology of Cancer*. Lugano: ESMO.

13.- Martínez MT, Roselló S, Cervantes A (2012) "Antimetabolites" in Sessa C, Gianni L, Garassino M, van Halteren H (eds) *Clinical pharmacology of anti-cancer agents*. Lugano: ESMO, pp: 53-68.

14.- Tabernero J, Cervantes A, van Halteren H (eds) (2016). *Gastrointestinal Tract Tumours - Essentials for clinicians*. Lugano: ESMO.

Author of the following chapters in this book:

15.- Gambardella V, Tarazona N, Cervantes A (2016) "Gastric cancer", pp: 22-27

16.- Roselló S, Cervantes A (2016). "Rectal câncer", pp: 33-36

Professional Associations

Sociedad Española de Oncología Médica
European Society for Medical Oncology
American Society of Clinical Oncology
American Association of Cancer Research

Research projects

- **National Funding**

1. TITLE: Estudio de la asociación del cáncer de mama con polimorfismos de brca1 y brca2 y genes que pueden modular la función transcripcional de brca1 y brca2.

01/0024-05

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2002 UNTIL 2004

2. TITLE: Proyecto para el estudio de las mutaciones de los genes MSH2 y MLH1, relacionadas con el cáncer de colon hereditario no asociado a poliposis.

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: SANOFI-RECHERCHE

DURATION FROM 2001 UNTIL 2001

3. TITLE: Análisis proteómico y metabolómico de linfocitos irradiados como factor predictivo en el diagnóstico del cáncer de mama. 04/1064

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2005 UNTIL 2007

4. TITLE: Red Temática de Investigación Cooperativa de Cáncer

PRINCIPAL INVESTIGATOR: Ana Lluch

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2007 UNTIL 2009

5. TITLE: Mecanismos de resistencia a inhibidores de EGFR. Estudio epigenómico y de acetilación de proteínas en líneas celulares KRAS mutado y salvaje, y su evaluación en pacientes con cáncer de colon. PS09/02480

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2010 UNTIL 2012

6. TITLE: Mecanismos de resistencia a inhibidores de EGFR. Estudio epigenómico y de acetilación de proteínas en líneas celulares K-Ras mutado y salvaje y su evaluación en pacientes con cáncer de colon ACOMP 12/069

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Conselleria de Educación de la Generalitat Valenciana

DURATION FROM 2012 UNTIL 2012

7. TITLE: Hiperacetilación de riboproteínas heterogéneas nucleares (hnRNPs) como vía final de resistencia a fármacos anti-EGFR en cáncer colorectal. PI12/02767

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2013 UNTIL 2015

8. TITLE: Estudio traslacional sobre la hiperacetilación de proteínas como vía final de resistencia a fármacos anti-EGFR a cánceres de alta incidencia clínica.

Prometeo/2013/005

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Generalitat Valenciana

DURATION FROM 2013 UNTIL 2015

9. TITLE: Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecaados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral. PI15/02180

PRINCIPAL INVESTIGATOR: Andrés Cervantes

SPONSOR: Instituto Salud Carlos III

DURATION FROM 2016 UNTIL 2018

10. TITLE: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en Biopsia líquida y modelos de organoides. PI18-01909
PRINCIPAL INVESTIGATOR: Andrés Cervantes
SPONSOR: Instituto Salud Carlos III
DURATION FROM 2019 UNTIL 2021

- **International Funding**

1. TITLE: Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
PRINCIPAL INVESTIGATOR: Josep Tabernero
SPONSOR: European Union
DURATION FROM 2015 UNTIL 2019

2. TITLE: Evolution of resistant clones to novel target-directed drugs in colorectal tumors. A genetic and epigenetic study of intratumoral heterogeneity dynamics. IntraColor AC15/00096
PRINCIPAL INVESTIGATOR: Andrés Cervantes
SPONSOR: Comisión Europea. DG Research and Innovation
DURATION FROM 2016 UNTIL 2019

3. TITLE: CeLac and European consortium for a personalized medicine approach to Gastric Cancer. LEGACy. GA 825832
PRINCIPAL INVESTIGATOR: Andrés Cervantes
SPONSOR: European Commission
DURATION FROM 2019 UNTIL 2022